Mechanisms of IgE XXXX .

@entity1 @entity32 @entity2023 @entity66 @entity566 @entity565 @entity2490 @entity56 @entity288
The prevalence of diseases such as @entity56 and @entity2490 continues to increase in the United States, affecting millions of @entity1 . It is well-established that @entity566 contributes to the pathogenesis of most @entity565 , especially in @entity1 and young adults. Despite current therapy (eg, inhaled corticosteroids, anti-leukotrienes, and bronchodilators), @entity1 with moderate to severe @entity565 remain symptomatic and experience frequent exacerbations of disease requiring oral @entity288 , emergency department treatments, and hospitalizations. @entity56 are traditionally referred to as immediate or type 1 hypersensitivity reactions, with IgE as a critical factor. IgE is involved in @entity32 , especially in early-phase response, but it may also be involved in the late-phase @entity56 response. A direct correlation between serum IgE levels and @entity565 exists. As logarithm IgE values increase, @entity565 prevalence increases linearly, even in @entity1 who are categorized as having @entity565 . In addition, there is a significant, although low association in @entity2023 with IgE levels and positive skin test reactivity to pollens. Recent advances in our understanding of the role of IgE in @entity32 have led to the development of a monoclonal antibody to IgE that reduces IgE levels, thereby @entity32 . This review aims to provide an overview of the basic science of the IgE molecule and the clinical efficacy of anti-IgE therapy in @entity56 and @entity66 .
